AU3353399A - Methods to potentiate intravenous estramustine phosphate - Google Patents
Methods to potentiate intravenous estramustine phosphate Download PDFInfo
- Publication number
- AU3353399A AU3353399A AU33533/99A AU3353399A AU3353399A AU 3353399 A AU3353399 A AU 3353399A AU 33533/99 A AU33533/99 A AU 33533/99A AU 3353399 A AU3353399 A AU 3353399A AU 3353399 A AU3353399 A AU 3353399A
- Authority
- AU
- Australia
- Prior art keywords
- estramustine
- cancer
- estramustine phosphate
- administered
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title claims description 167
- 229960004750 estramustine phosphate Drugs 0.000 title claims description 156
- 238000000034 method Methods 0.000 title claims description 109
- 238000001990 intravenous administration Methods 0.000 title claims description 72
- 230000003389 potentiating effect Effects 0.000 title claims description 8
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 67
- 229960001842 estramustine Drugs 0.000 claims description 66
- 238000001802 infusion Methods 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 108010048134 estramustine-binding protein Proteins 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 31
- 206010060862 Prostate cancer Diseases 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 229940127089 cytotoxic agent Drugs 0.000 claims description 26
- AXWYROHIFVWHMR-UGTOYMOASA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] n,n-bis(2-chloroethyl)carbamate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AXWYROHIFVWHMR-UGTOYMOASA-N 0.000 claims description 24
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 21
- 230000008901 benefit Effects 0.000 claims description 19
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 18
- 239000002502 liposome Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 15
- 239000002207 metabolite Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 230000003442 weekly effect Effects 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 229940123237 Taxane Drugs 0.000 claims description 8
- 239000003080 antimitotic agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
- 229960005420 etoposide Drugs 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 229960003048 vinblastine Drugs 0.000 claims description 6
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 5
- 230000002459 sustained effect Effects 0.000 claims description 5
- 201000002327 urinary tract obstruction Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229940086322 navelbine Drugs 0.000 claims description 3
- 230000009044 synergistic interaction Effects 0.000 claims description 3
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 3
- 229940044684 anti-microtubule agent Drugs 0.000 claims 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 7
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 10
- 102100038358 Prostate-specific antigen Human genes 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000002307 prostate Anatomy 0.000 description 8
- 230000003252 repetitive effect Effects 0.000 description 8
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000004688 microtubule Anatomy 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000031864 metaphase Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001946 anti-microtubular Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000009448 modified atmosphere packaging Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- 101000841393 Candida albicans Probable NADPH dehydrogenase Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000010224 Castration-Resistant Prostatic Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- -1 estromustine phosphate metabolites Chemical class 0.000 description 1
- 150000002167 estrones Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
WO 99/49869 PCT/US99/04275 TITLE OF THE INVENTION METHODS TO POTENTIATE INTRAVENOUS ESTRAMUSTINE PHOSPHATE 5 This application claims priority to U. S. Provisional Application serial No. 60/079.542. which was filed on March 27. 1998. BACKGROUND OF THE INVENTION Field of the Invention: The present invention relates to the use of estramustine phosphate, a non 10 nitrogen mustard carbamate derivative of estradiol- I 7b-phosphate. as a high dose infusion. The present invention further relates to methods to potentiate intravenously administered estramustine phosphate and to methods for treating cancer by intravenously administering estramustine phosphate. Discussion of the Background: 15 Cytotoxic effects have been shown to be due to the intact estramustine molecule (Hartley-Asp, 1982). Tissue culture studies have shown that estramustine (EM) is an anti-mitotic agent. causing a dose-dependent blocking of tumor cell division in the metaphase (Hartley-Asp. 1984). Metaphase arrest is known to be caused by an interference of drugs with the microtubule structure that forms the 20 mitotic spindle. It has been shown, with the help of immunohistochemistry. that dose dependent disturbances of interphase microtubules occur in cultured human prostatic cells (Mareel 1988. Dahllof 1993). Treatment with EM in vitro inhibited the assembly of microtubules composed of only tubulin demonstrating a direct interaction with tubulin (Dahllof 1993). In addition, an interaction with microtubule associated
I
WO 99/49869 PCT/US99/04275 proteins (MAPs) has been demonstrated (Steams 1988). MAPs are high molecular weight proteins that are believed to be important in stabilizing microtubules. That EM exhibits the mechanism of action of an anti-mitotic agent has been confirmed in vivo (Ekl6v. 1992). 5 Estramustine phosphate is thus an anti-mitotic agent currently used in the treatment of advanced adenocarcinoma of the prostate. As a single agent. its activity in hormone-refractory prostate cancer is comparable to that of several other cytotoxic agents that have been studied in a series of multi-institutional, randomized trials by the National Prostatic Cancer Project (Murphy, 1983). While the drug is usually 10 administered orally at a dose of 10-15 mg/kg/day, it is approved for intravenous administration in several countries. However. estramustine phosphate when administered intravenously has been used at dosages and according to a schedule paralleling the oral administration for the drug, i.e. at recommended dosages of 300 600 mg daily given intravenously and usually repetitively over for several consecutive 15 days. This is then followed by orally administered drug. In the published material, details from about 500 patients who have been treated with the intravenous formulation initially which was then followed by oral treatment can be found. Induction schedules employing 300-600 nmg intravenous daily for 7-21 days. followed by daily oral doses, were typical in these studies. The drug 20 was administered as a slow intravenous injection or as a bolus at 300 mg/day. and thrombophlebitis and local irritation at the peripheral intravenous injection sites were considered major limitations of drug administration requiring the establishment of central line administration in many patients or discontinuation of treatment. At 450 mg/day. Nagel and Klln (1977) stated that this led to so "'severe gastrointestinal WO 99/49869 PCT/US99/04275 problems that 300 mg/day was taken as the maximum intravenous daily dose." In a compilation, by Andersson et al. of 245 patients receiving 300-600 mg/day for 21 days followed by the same dose once or twice weekly for 2 months. 20% of the patients exhibited thrombophlebitis. 17% exhibited gastrointestinal problems and 9% 5 exhibited liver disturbances. Toxicities resulting from such repetitive dosing schedules often require drug discontinuation (Lundgren. 1995). Maier (1990), administered daily intravenous doses of 900 mg/day for 7-10 days. followed by oral therapy, without reporting phlebitis but severe liver problems did occur in 11 of 18 patients (61%) with one death due to toxic liver failure. 10 The state of the art thus typically utilized intravenous estramustine phosphate formulations as a single-agent method for initiating a long term oral estramustine therapy. Furthermore, intravenous administration of estramustine phosphate at higher dosages is generally considered prohibitive due to toxicity. It is neither known nor obvious to the art that single dose. high-dosage administration of estramustine 15 phosphate is feasible intravenously. While dosing up to 1200 mg/m 2 have been given orally (Keren-Rosenberg. 1997). differences in drug metabolism and bioavailability do not permit extrapolation to the high dose intravenous formulation, with relative bioavailability of estromustine after oral administration found to be only 44%. (Gunnarsson, 1984). with the phosphate moiety dephosphorylated in the oral 20 formulation in contrast to the intravenous formulation. Furthermore, it is not known in the art that intravenous estramustine phosphate can be used in combinational chemotherapy regimens, including the use of higher dose intravenous estramustine phosphate. Furthermore. it is not known to the art that intravenous estramustine phosphate has clinical utility for cancers other than for the prostate cancer indication. 3 WO 99/49869 PCT/US99/04275 In previous work. Dr. Beryl Hartley-Asp, a co-inventor of this invention, was the tirst to recognize the synergistic potential of estramustine phosphate with other cytotoxic agents. (Mareel 1988). In several experiments. it was demonstrated that prolonged exposure to estramustine was necessary to achieve potentiation. 5 Consequently. daily dosing was deemed necessary leading to the use of the ORAL preparation as previous data from the intravenous (IV) preparation suggested that achievement of constant high levels would not be clinically achievable with IV dosing. Additive and possibly synergistic antimicrotubule effects in cells in vitro have 10 been shown for estramustine and many other cytotoxic agents, (Marcel 1988. Speicher 1992. Pienta 1993, Batra,1996). Thus, the combination of estramustine phosphate with other drugs in humans has been carried out using ORAL administration of estramustine phosphate. Phase II trials (Seidman, 1992, Hudes, 1992. Pienta. 1994. Hudes, 1996) with Estramustine phosphate combined with vinblastine. have been 15 carried out in hormone refractory prostate cancer. In these trials a 50-75% decrease in prostate specific antigen was demonstrated among 88 patients. The most frequent toxicity was mild to moderate nausea. Of particular note is the 10.5%0 (4/37) incidence of significant cardiovascular toxicity including one deep venous thrombosis (DVT). one myocardial infarction, one episode of congestive heart failure, and one 20 reversible neurologic event which required stopping therapy in these patients and which can be attributed to estramustine phosphate. In another Phase II trial carried out by Pienta et al (1994). estramustine phosphate (oral) was combined with Etoposide. Fifty two patients were evaluable: including 20 patients with soft tissue disease, in which 3 complete responses (CR) (15%) and 6 partial responses (PR) (30%) were 4 WO 99/49869 PCT/US99/04275 observed. In 32 patients with bone metastases 8 patients improved (25%), and 12 patients were stable (38%). Overall 13 men (25%) had a 75% decrease in prostate specific antigen, and 28 men (54%) had a 50% decrease. A Phase I-II study of Taxol (Hudes, 1992) and estramustine phosphate was carried out in seventeen patients with hormone refractory prostate cancer. Six patients had measurable disease and 3 of these obtained a PR of 2+. 6. and 8 months. Prostate specific antigen (PSA) decreased by > 50% in 58.8%. Median duration of response was 7 months. Grade 3 4 granulocytopenia and mucositis occurred in 2 patients. nausea grade 1-2 (70.5%) and grade 3 in one patient. Edema was seen in 8 patients (47%) and transient hepatic 10 enzyme elevation of grade 1-3 in 6 patients (35.2%). In a recent study, Petrvlak et al., (1997), using escalating doses of docetaxel with estramustine phosphate given orally demonstrated an overall prostate specific antigen response rate of 62%. In patients with bidimensionally measurable disease. 3 (43%) achieved a partial response in lymph nodes, and 1 achieved a minor response in 15 ischial mass. This demonstrates that combination treatment with ORAL estramustine phosphate is efficacious. However, combinations of intravenous estramustine phosphate with these cytotoxic agents are not known to the art. Differences in the metabolism, particularly regarding the phosphate moiety, in the oral versus intravenous estramustine phosphate formulations make combinational therapies with 20 the intravenous formulation non-obvious. In contrast to other anti-mitotic agents, the effect of estramustine phosphate appears to be dependent on the presence of the estramustine binding protein (EMBP) (Ekldv, 1996). This is found under normal conditions only in the prostate (Forsgren. 1979, Flucher. 1989). However, a similar protein has also been identified in many 5 WO 99/49869 PCT/US99/04275 cancerous tissues, as well as prostate tumors, such as lung, breast glioma. colon, pancreas (Bj6rk.1991. Bergh 1988. Ekl6v 1996. Edgren 1996. Von Schoultz. 1994. Bergenheim. 1993). This protein binds estra- and estro-mustine (EaM and EoM) with very high affinity and is thought to be responsible for the selective retention of EoM in the prostate tumor, where a ratio of 1:6 to 1:11 plasma/tumor has been found in prostate cancer patients treated with estramustine phosphate oral and intravenously, respectively (Norlen 1988.Walz 1988). Recently, we have demonstrated a correlation between the levels of EMBP and the levels of EaM and EoM in human prostate tumors after a single intravenous estramustine phosphate dose to patients before 10 radical prostatectomy. indicating that EMBP could be the cause of drug retention (Walz. 1996). BRIEF DESCRIPTION OF THE FIGURES A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same become better understood by I5 reference to the following detailed description when considered in connection with the accompanying drawings, wherein: Figure 1 illustrates the concentration of estramustine phosphate after a single intravenous dose of Estracvt (mean ± SEM. N = 4 + 4 + 3) given at a dosage of 1000 mg (range 980-1070 mg), 1000 mg/im 2 . and 1500 mg/m-: and 20 Figure 2 illustrates the concentration of estromustine after a single intravenous dose of Estracyt (mean ± SEM. n = 4 + 4 + 3) given at a dosage of 1 0 00 mg (range 980-1070 mg), 1000 mg/m'. and 1500 mg/m-. 6 WO 99/49869 PCT/US99/04275 SUMMARY OF THE INVENTION The present invention describes methods of potentiating the therapeutic use and efficacy of intravenously administered estramustine phosphate. It provides for the intravenous administration of estramustine phosphate in dosages exceeding 1300 mg. It also provides for intravenous administration of estramustine phosphate at dosages exceeding 950 mg/m- (milligrams per square meter of body surface area). It further provides for administration of high dose intravenous estramustine phosphate as a single dose, which may further be administered on a weekly or longer schedule. The present invention enables optimization of pharmacokinetics as to maximize 10 therapeutic advantage, and further enables use of intravenous estramustine phosphate in combination with other therapies, including other chemotherapies, providing further improved therapeutic benefit. The present invention enables use of intravenous estramustine phosphate as therapy for multiple tumor types, including prostate, breast, lung, ovarian. colorectal. melanoma, pancreatic, and brain cancers. 15 Thus. one application of the present invention is to provide high dose estramustine phosphate therapy intravenously, wherein the dose exceeds 950 mg/m-. Another application is to provide a schedule of intravenous administration, whereby that schedule enables optimization of pharmacokinetics of estramustine phosphate and its metabolites at minimal toxicity, and further whereby said 20 optimization permits convenient and efficacious combination regimens of therapy. Thus. an application of the present invention permits the use of intravenous estramustine phosphate in combination with other therapeutic regimens, including cytotoxic chemotherapy. Another application of the present invention is to provide a method which 7 WO 99/49869 PCT/US99/04275 increases binding saturation and prolongs binding duration of estramustine phosphate or its metabolites to estramustine binding protein or estramustine binding protein-like protein (EMBP). Thereby, the present invention provides application to treatment of cancers 5 having EMBP. including but not limited to prostate, breast, lung, ovarian, colorectal, melanoma, pancreatic. and brain cancers, by intravenous administration. Another application of the present invention is to provide a method of rapidly relieving symptoms secondary to cancer, inclusive of but not limited to cancer induced pain and urinary obstruction. 10 Further, the present invention enables these applications for use of intravenous estramustine phosphate independent of the formulation. Thereby, the present invention provides for the infusion of estramustine phosphate as free drug, as protein bound drug, or as drug within liposomes. Thereby, the present invention describes a formulation of estramustine 15 phosphate wherein the estramustine phosphate is administered intravenously in conjunction with liposomes. Thus, the method of the present invention in which doses above 900 mg/m 2 (generally greater than 1300 mg per dose) can be administered safely and within an effective schedule is extremely unexpected. 20 The present invention teaches the advantage of intravenous estramustine in combination with other chemotherapy agents. The present invention further teaches the advantage of high dose intravenous estramustine in combination with other chemotherapeutic agents. We teach in this invention that intravenous estramustine phosphate may be 8 WO 99/49869 PCT/US99/04275 used to treat tumors having elevated EMBP-like protein (herein referred to simply as EMBP). The novel and non-obvious applications of the present invention can be recognized from a comparison of the pharmacokinetic data following oral 5 administration estramustine phosphate with that following high-dose intravenous administration of estramustine phosphate. The pharmacokinetic and toxicity data regarding high-dose intravenous estramustine phosphate is not known to the art. Dephosphorylation of estramustine phosphate to estramustine (EM), followed by oxidation at the 17 position to estromustine (EoM). the estrone analogue of EM. are 10 the major metabolic steps after administration of oral estramustine phosphate in man. EoM is the predominant metabolite found in plasma when estramustine phosphate is administered on the daily oral schedule. The relative bioavailability based on estromustine is approximately 44%(Gunnarsson, 1984). After intravenous administration estramustine phosphate is initially found in plasma but is rapidly 15 hydrolyzed to the same metabolites as are found after oral administration, the major metabolite being estromustine. Both estramustine and estromustine are further metabolized by cleavage of the carbamic ester to yield approximately 15% estradiol and estrone. respectively (Gunnarsson, 1981. 1984). We have demonstrated an unexpected prolonged availability of the major metabolite estromustine following 20 high-dose intravenous administration, which can lead to unexpected clinical benefits. Previous data from patients treated with a single intravenous dose of 300 mg demonstrated that the elimination of estromustine had a half lives of 10-20 hours. The main route of elimination was metabolism of estromustine phosphate to estramustine, estromustine. estradiol and estrone. The data of particular importance for the efficacy 9 WO 99/49869 PCT/US99/04275 of estramustine phosphate was the half lives of estramustine phosphate. (Figure 1), and the major cytotoxic metabolite estromustine (Figure 2). By application of the methods of this invention. we now demonstrate the novel finding that after a single high intravenous dose of estramustine phosphate at 1000mg/m- it was found that the 5 half life of estromustine was approximately 100 hours. (Figure 2). This finding further enables therapeutic applications of high-dose intravenous estramustine phosphate. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention teaches the ability to administer estramustine phosphate 10 at doses above 950 mg/m- (i.e., greater than 1300 mg). The method of the present invention is performed as follows. In the preferred method, estramustine phosphate is administered at a single infusion dosage exceeding 950 mg/m 2 . Intravenous administration is performed either through a central or peripheral intravenous route. During preparation of the intended drug, the contents of 15 packaged estramustine phosphate intended for intravenous usage are dissolved, wherein the packaged contents may consist of but are not limited to a lyophilized powder of the meglumine salts in vials of estramustine phosphate. or similar freeze dried estramustine phosphate which are first dissolved in sterile water such as 5 ml sterile water per 300 inmg estramustine phosphate. or in 5%O dextrose in water for 20 intravenous administration. In the preferred method. 5% dextrose in water is used as the diluent. In the preferred method, during preparation of the dissolved drug the preparation should not be shaken, but should be slowly inverted to mix. The solution is then given as an intravenous infusion with the preferred duration of infusion time 10 WO 99/49869 PCT/US99/04275 being 30 minutes to 3 hours, whereby infusion over 1-2 hours is a safe and convenient method. Saline solution may result in drug precipitation and thereby its use is not preferred in the infusion. When estramustine phosphate is administered through a peripheral intravenous 5 route, it is preferred that a longer duration of infusion and greater total infusional volume be utilized to minimize vascular irritation. Alternatively, the estramustine phosphate solution can be mixed with various amounts but preferably 3-5% human albumin or other plasma proteins including synthetic plasma proteins to achieve protein binding of the estramustine phosphate and therefore minimize any potential 10 vascular damage. The invention may be further realized using other preparations or formulations of estramustine phosphate. One particularly advantageous preparation of the chemotherapeutic agent estramustine phosphate which enables infusion of estramustine phosphate through either a peripheral or central vein, both at high doses 15 and also doses less than 1300 mg. involves the infusion of estramustine phosphate in conjunction with liposomes (herein referred to as liposome encapsulated estramustine phosphate or liposomal estramustine). In one preferred method of preparing liposomal estramustine, estramustine phosphate solution is first prepared in the manner described above and then injected into a vial containing empty liposomes 20 available as a lyophilized powder. Following adequate hydration of the liposomes, the vials are vortexed and sonicated. followed by infusion into the patient. When estramustine phosphate is administered through a central venous route, said administration may be performed through either a temporary or permanent venous access device, including but not limited to a triple lumen catheter. Hickman 11 WO 99/49869 PCT/US99/04275 catheter, subclavian line. jugular line, or medi-port. Said administration may be but is not necessarily performed concomitant with anticoagulant therapy or with the addition of varying amounts but preferably 3-5% human albumin or other plasma proteins or liposomal estramustine to minimize any potential vascular damage in a given patient. 5 While the dosage of estramustine phosphate in the present invention is greater than 1300 mg, it is preferred that the patient be treated at a dose exceeding 950 mg/m-. Thereby, one preferred method is to administer a single intravenous dosage of 1000 mg/m 2 . Another preferred method is to administer a single intravenous dosage of 1500 mg/m 2 . Furthermore, a dosage of 2000 mg/m - may be administered. However. 10 the invention is inclusive of other dosages above 950 mg/m' and the preferred dosages are not to imply limitation. The most preferred schedule of estramustine phosphate administration in the invention is a single infusion given once weekly to a maximal dose of 4000 mng or 3500 mg/m 2 . Another preferred schedule is administration of a single drug infusion 15 once every two weeks. Another preferred schedule is administration of a single drug infusion once every three weeks. Another preferred schedule is administration of a single drug infusion once every four weeks. One schedule may be preferred over another in consideration of schedules with other concomitant therapy. These schedules may repeat in a serial or repetitive fashion. 20 The invention described herein enables methods to prolong blood and/or tissue levels at high elevations for estramustine phosphate metabolites. including estromustine. estramustine. estrone and estradiol. Thereby. enhanced synergistic interactions with other therapies is enabled, wherein such other therapies include but are not limited to chemotherapy, radiotherapy. monoclonal antibodies, and biologic 12 WO 99/49869 PCT/US99/04275 therapies. The present invention provides maximization of therapeutic benefit by prolongation of elevated blood and tissue levels of estramustine phosphate and its metabolites. Thereby, maximization of therapeutic benefit is achieved wherein estramustine phosphate is administered intravenously at dosages exceeding 950 mg/mn. which are administered in combination with other cancer therapies, inclusive but not limited to radiotherapy, chemotherapy. monoclonal antibodies, and biologic therapies. In the preferred method, therapeutic benefit is potentiated by administering intravenous estramustine phosphate at single dosages exceeding 950 mg/m', with 1 0 other cvtotoxic chemotherapies. In the preferred method said combination is achieved by administering intravenous estramustine phosphate within 3 days of the other chemotherapeutic agents, preferably on the day of, or the day prior to administration of the other chemotherapeutic agents. A particularly preferred method is achieved when the other chemotherapeutic agents consist of anti-mitotic agents or anti 15 microtubule agents, inclusive of but not limited to taxanes, including taxol and taxotere. and agents including vinblastine. vincristine, etoposide. navelbine. doxorubicin, irinotecan (CPT-11), and liposome encapsulated chemotherapeutic agents. including liposome encapsulated taxanes such as liposome encapsulated paclitaxel. It may be further beneficial if a combination with a monoclonal therapy is 20 utilized, that the monoclonal agent include a radionucleotide or an anti-growth factor agent. Plasma or serum levels of estromustine are further sustained when estramustine phosphate is administered intravenously as a single infusion at a dosage exceeding 950 mg/m'. The infusion may optionally be repeated in a serial or 13 WO 99/49869 PCT/US99/04275 repetitive manner to maintain elevated blood levels of the estromustine phosphate metabolites. Sustained levels of estramustine phosphate and its metabolites thereby enable sustained therapeutic benefit. The present invention thereby provides a method to increase the binding saturation of estramustine or its metabolites to estramustine binding protein or like protein by administering estramustine phosphate intravenously at a single infusion dose exceeding 950 mg/m 2 . Similarly, the binding duration of estramustine phosphate or its metabolites to estramustine binding protein or estramustine binding protein-like protein (EMBP) is increased in the invention by administering the drug at intravenous 10 dosages exceeding 950 mg/m 2 . Thereby. all cancers having either estramustine binding protein or estramustine binding protein like-protein may be treated by intravenous estramustine phosphate. It is particularly preferred to treat prostate cancer in such manner. It is further preferred to treat breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, and cancers of the brain in such 15 manner. It is particularly preferred that estramustine phosphate be administered intravenously wherein the single dosage exceeds 950 mg/m 2 when treating cancers having either estramustine binding protein or estramustine binding protein like protein, inclusive of but not limited to the group of cancers including prostate cancer. breast cancer, ovarian cancer, pancreatic cancer, melanoma. lung cancer. and cancers 20 of the brain. Said cancers may further be treated using liposomal estramustine. either as a single agent or in combination with other chemotherapies. Said administrations are preferably repeated in serial or repetitive fashion at schedules of the invention. with or without combination of other therapies. Thus. said schedules may include 14 WO 99/49869 PCT/US99/04275 combinational treatment of intravenous estramustine phosphate with other chemotherapeutic therapies given on a once weekly, a once every two week. a once every three week. or a once every four week schedule, and variations therein. It is particularly preferred that intravenously administered estramustine 5 phosphate be administered in combination with other chemotherapeutic cytotoxic agents when used in the treatment of prostate cancer, breast cancer. melanoma, lung cancer, pancreatic cancer. colorectal cancer, ovarian, and cancers of the brain. It is further particularly preferred that intravenously administered estramustine phosphate be administered in combination with radiation when used in the treatment of prostate 10 cancer, breast cancer, lung cancer, pancreatic cancer, colorectal cancer, and cancers of the brain. It is further preferred that in treating cancers having estramustine binding protein or estramustine binding protein like-protein, including prostate cancer, breast cancer, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, and cancers of the brain, estramustine phosphate be administered at intravenous dosages exceeding I15 950 mg/m 2 when used in combination with other cancer therapies. The present invention enables both objective and subjective therapeutic benefit. Benefit achieved may relate to reduction of tumor size, improved quality of life, reduction of tumor obstruction, such as urinary obstruction, reduction of cancer induced pain, improved survival, reduction in time to cancer recurrence, or other 20 evidence of improvement. In particular, rapid objective or subjective therapeutic benefit is achieved by administering estramustine phosphate intravenously at a dosage exceeding 950 mgi/m 2 . either as a single agent or preferably in combination with other cancer therapies. Thereby the invention enables rapid relief of cancer-induced urinary obstruction, and rapid relief of cancer-induced pain. 15 WO 99/49869 PCT/US99/04275 Other features of the invention will become apparent in the course of the lbllowing descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof EXAMPLES 5 The following clinical cases are provided by way of example and not limitation. Example 1: Two patients with advanced metastatic prostate cancer were treated with estramustine phosphate intravenously given through a central line. The patients received an estramustine phosphate dosage of 2500 mg/m 2 . Estramustine 10 phosphate was administered as a single infusion on a weekly schedule in a repetitive fashion. Each infusional dose was administered over a 90 minute infusion. The infusions were well tolerated without serious toxicity and both patients demonstrated a response (reduction) in their prostate specific antigen (PSA). Example 2: Three patients with advanced metastatic prostate cancer were 15 treated with estramustine phosphate administered intravenously through a central line at a dosage of 1000 mg/m 2 . Estramustine phosphate was administered as a single infusion on a weekly schedule in a repetitive fashion. Each infusional dose was administered over a 30 minute infusion. The infusions were well tolerated with several patients demonstrating PSA response. 20 Example 3: Three patients with advanced metastatic prostate cancer were treated with estramustine phosphate administered intravenously through a central line 16 WO 99/49869 PCT/US99/04275 at a dosage of 1500 mg,,m'. Estramustine phosphate was administered as a single infusion on a weekly schedule in a repetitive fashion. The infusional dose was administered either over 30 minutes or over 1 hour. The infusions were well tolerated with one patient demonstrating a response in bulky tumor adenopathy. Example 4: Three patients with advanced metastatic prostate cancer were treated with estramustine phosphate intravenously given through a central line. The patients received an estramustine phosphate dosage of 2000 mg/m'. Estramustine phosphate was administered as a single infusion on a weekly schedule in a repetitive fashion. Each infusional dose was administered over a 60 minute infusion. An anti 10 thrombotic agent was additionally administered for venous thrombosis prophylaxis. The estramustine phosphate infusions were well tolerated without serious toxicity, and with evidence of PSA response. REFERENCES Andersson SB. Lundgren R. Svensson L: Gas chromatographic determination 15 of four metabolites of estramustine phosphate on plasma. Acta Pharm Suec 19:1-10, 1982 Batra S. Karisson R. Witt L: Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 68:1-6. 1996 20 Bergenheim AT. Gunnarsson PO, Edman K. von Schoultz E. Hariz MI Henriksson R: Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumors in humans. Br J Cancer 67:358-361. 1993 17 WO 99/49869 PCT/US99/04275 Bergh J. Bj6rk P. Westlin J-E. Nilsson S: Expression of an Estramustine binding associated protein in human lung cancer cell lines. Cancer Res 48:4615-4619, 1988 Bjbrk P. Borg A. Fern6 M. Nilsson S: Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma. Anticancer Res 11 (3): 1173-1182. 1991 Bj6rk P, Jansson U. Andren-Sandberg A: Binding sites for the cytotoxic metabolites of Estramustine phosphate (Estracyt®) in rat and human pancreas that are distinct from pancreatic Estrogen-binding protein. Pancreas 6:1:77-89, 1991 10 Dahll6f B. Hartley-Asp B. Billstrom A. Cabral F: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581, 1993 Edgren M. Westlin JE. Letocha H et al.: Estramustine-binding protein (EMBP) in renal cell carcinoma immunohistochemistry, immunoscintigraphy and in vitro estramustine effects. Acta Oncol 35(4):483-488, 1996 15 Ekl6v S et al., Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. The Prostate 20:43-50. 1992 Eklav S. Mahdy E, Wester K et al.: Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest. Anticancer Res 16(4A):1819-1822, 1996 20 FlItichter S, Nelde HJ. Bj$rk P et al.: Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: An immunohistochemical study. The Prostate 14:27-43, 1989 Forsgren B. Bjbrk P. Carlstrdm K. Gustafsson JA. Pousette A. Hdgberg B: Purification and distribution of a major protein in rat prostate that binds estramustine. 18 WO 99/49869 PCT/US99/04275 a nitrogen mustard derivative of estradiol-17 3. Proc. Natl. Acad. Sci USA: 76:3149 3153, 1979 Gunnarsson PO. Andersson S-B. Johansson S-A et al.: Pharmacokinetics of estramustine phosphate (Estracyt®R) in prostatic cancer patients. Eur J Clin Pharmacol 5 26:113-119. 1984 Gunnarsson PO, Plym Forshell G. Fritjofsson A. Norlen BJ: Plasma concentration of Estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of Estramustine phosphate (Estracyt@). Scand J Urol Nephrol 15:201-206. 1981 10 Hartley-Asp B: Estramustine induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. The Prostate 5:93-100. 1984 Hartley-Asp B. Gunnarsson PO: Growth and cell survival following treatment with estramustine, nor-nitrogen mustard. estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urology 127:818-822, 1982 15 Hudes G, Obasaju C. Chapman A. Gallo J. McAleer C, Greenberg R: Phase I study of Paclitaxel and Estramustine: Preliminary activity in hormone refractory prostate cancer. Sem Oncol, Vol 22:3. Supply 6:6-11, 1995 Hudes GR. Greenberg R. Krigel RL. Fox S. et al.: Phase II study of estramustine and vinblastine. two microtubule inhibitors, in hormone-refractory 20 prostate cancer. J Clin Oncol 10:1754-1761. 1992 Keren-Rosenberg, S, Muggia. FM: Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: A phase I Study Seminars in Oncology 24:5 S3-26 - S3-29. 1997 Lindberg B: Treatment of rapidly progressing prostatic carcinoma with 19 WO 99/49869 PCT/US99/04275 Estracyt. Journal of Urol 108:303-305. 1972 Maier U. Hienert G. Simak R: Estramustine phosphate in secondary hormone resistant carcinoma of the prostate. Eur Urol 17:216-218. 1990 Mareel MM. Storme GA, Dragonetti CH, De Bruvne GK. Hartley-Asp B, 5 Segers JL. Rabaey ML. Antiinvasive activity of estramustine on malignant MO 4 mouse cells and DU 145 human prostate carcinoma cells in vitro. Cancer Res 48:1842-1849, 1988 Murphy GP. Slack NH. Mittleman A: Experiences with Estramustine Phosphate (Estracyt. Emcyt) in prostate cancer. Seminars in oncology 10(3) Suppl 3. 10 34-42, 1983 Nagel R. K611n C-P: Treatment of advanced carcinoma of the prostate with estramustine phosphate. British Journal of Urol 49:73-79. 1977 Norlen, B.J., Andersson S.B., Bjbrk P., Gunnarsson P.O., Fritjofsson A. Uptake of Estramustine phosphate (Estracyt) metabolites in prostate cancer. Journal of 15 Urology 140:1058-1062. 1988 Petrylak DP. Shelton GB. Mac Arthur RB et al.: Phase I trial of Docetaxel Estramustine in androgen insensitive prostate cancer. Cancer Investigation 16. Supp 1 p 62. 1 9 9 7 Pienta KJ. Lehr JE: Inhibition of prostate cancer growth by estramustine and 20 etoposide: Evidence for interaction at the nuclear matrix. Journal of Urol 149:1622 1625, 1993 Pienta KJ. Redman B. Hussain M, Cummings G et al.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012. 1994 20 WO 99/49869 PCT/US99/04275 Seidman AD. Scher HI. Petrvlak D. Dershaw DD, Curley T: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934. 1992 Speicher LA, Barone L. Tew KD: Combined antimicrotubule activity of 5 estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433 4440. 1992 Stearns M. Tew KD: Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Science 89:33 1-342. 1988 von Schoultz E. Carlstr6m K. Henriksson R et al.: Estramustine binding I 0 protein in primary tumors and metastases of malignant melanoma. Melanoma Res 4(6):401-405, 1994 Walz PH. Bj6irk P, Edman K, Gunnarsson PO, Hartley-Asp B: Uptake and distribution of the estramustine-phosphate metabolite estramustine after single-dose injection in patients with prostatic cancer. Akt Urol 27:92-93, 1996 15 Lundgren, R. Estracyt intravenost for behandling av hormonreftraktarprostatacancer: Svenska Lakaresallskapets Rikstamma. 1995 This application is based on U. S. Provisional Application serial No. 60/079.542. which was filed on March 27. 1998. which is incorporated herein by reference in its entirety. 20 Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein. 21
Claims (90)
1. A method of administering estramustine phosphate as an intravenous dose, whereby the dosage of a single infusion exceeds 1300 mg.
2. A method of administering estramustine phosphate as an intravenous dose, 5 whereby the dosage of a single infusion exceeds 950 mg/m 2 .
3. The method of claims 1 or 2, wherein estramustine phosphate is administered as a single infusion on a once weekly schedule.
4. The method of claims 1 or 2, wherein estramustine phosphate is administered as a single infusion on a once every two week schedule. 10
5. The method of claims 1 or 2, wherein estramustine phosphate is administered as a single infusion on a once every three week schedule.
6. The method of claims 1 or 2, wherein estramustine phosphate is administered as a single infusion on a once every four week schedule.
7. The method of claims 1 or 2, wherein estramustine phosphate is 15 administered in combination with other anti-cancer therapies.
8. The method of claim 7, wherein estramustine phosphate is administered intravenously in combination with other chemotherapeutic agents. 22 WO 99/49869 PCT/US99/04275
9. A method of potentiating the therapeutic benefit of a multi-drug chemotherapeutic regimen, wherein one of the drugs in the regimen comprises estramustine, by administering estramustine phosphate as an intravenous formulation.
10. The method of claim 9, wherein said intravenous formulation comprises 5 estramustine phosphate given at high dose.
11. The method of claim 9, wherein another drug in the regimen comprises an anti-mitotic agent or anti-microtubule agent.
12. The method of claim 10, wherein the dosage of a single infusion of estramustine phosphate exceeds 1300 mg. 10
13. The method of claim 10, wherein the dosage of a single infusion of estramustine phosphate exceeds 950 mg/m 2 .
14. A method to produce prolonged elevated plasma levels of estramustine to promote synergistic interaction between estramustine and a second chemotherapeutic agent, wherein: 15 estramustine is administered as an intravenous formulation, and estramustine is administered on the day of, or within 3 days of administration of said second chemotherapeutic agent.
15. The method of claim 14, wherein said second chemotherapeutic agent 23 WO 99/49869 PCT/US99/04275 comprises an anti-mitotic agent or anti-microtubule agent.
16. The method of claim 14, wherein the intravenous formulation comprises estramustine phosphate.
17. The method of claim 16, wherein the dosage of a single infusion of 5 estramustine phosphate exceeds 1300 mg.
18. The method of claim 16, wherein the dosage of a single infusion of estramustine phosphate exceeds 950 mg/m 2 .
19. A method to produce elevated plasma levels of the estramustine metabolite estromustine, to promote synergistic interaction between estromustine and 10 a second chemotherapeutic agent, wherein: estrastine is administered as an intravenous formulation; and estramustine is administered on the day of, or within 3 days of administration of said second therapeutic agent.
20. The method of claim 19, wherein said second therapeutic agent comprises 15 an anti-mitotic agent or anti-microtubule agent.
21. The method of claim 19, wherein the intravenous formulation comprises estramustine phosphate. 24 WO 99/49869 PCT/US99/04275
22. The method of claim 21. wherein the dosage of a single infusion of estramustine phosphate exceeds 1300 mg.
23. The method of claim 21, wherein the dosage of a single infusion of estramustine phosphate exceeds 950 mg/m 2 .
24. A method according to claim 14 to potentiate therapeutic benefit.
25. A method according to claim 19 to potentiate therapeutic benefit.
26. A method to sustain plasma levels of estramustine and estromustine. wherein estramustine phosphate is administered intravenously as a single infusion at a dosage exceeding 1300 mg; optionally repeating the infusion in a serial manner. 10
27. A method to sustain plasma levels of estramustine and estromustine, wherein estramustine phosphate is administered intravenously as a single infusion at a dosage exceeding 950 mg/m', optionally repeating the infusion in a serial manner.
28. A method according to claim 26. wherein therapeutic benefit is sustained.
29. A method according to claim 27. wherein therapeutic benefit is sustained. 15
30. A method of increasing binding saturation ofestramustine to estramustine binding protein, or like-protein wherein: 25 WO 99/49869 PCT/US99/04275 estramustine is administered as an intravenous formulation as estramustine phosphate at a single infusion dosage exceeding 1300 mg; and binding saturation of estramustine binding protein is thereby enhanced.
31. A method of increasing binding saturation of estramustine or its 5 metabolites to estramustine binding protein, or like-protein wherein: estramustine is administered as an intravenous formulation as estramustine phosphate at a single infusion dosage exceeding 950 mg/m 2 ; and binding saturation of estramustine binding protein is thereby enhanced.
32. A method of prolonging binding duration of estramustine or its 10 metabolites to estramustine binding protein, or like-protein wherein: estramustine is administered as an intravenous formulation as estramustine phosphate at a single infusion dosage exceeding 1300 mng; and binding duration of estramustine binding protein is thereby prolonged.
33. A method of prolonging binding duration of estramustine or its 15 metabolites to estramustine binding protein, or like-protein wherein: estramustine is administered as an intravenous formulation as estramustine phosphate at a single infusion dosage exceeding 950 mg/m: and binding duration of estramustinc binding protein is thereby prolonged.
34. The method of claim 30. wherein the method is used to treat a cancer 20 having estramustine binding protein, or estramustine binding protein-like protein. 26 WO 99/49869 PCT/US99/04275
35. The method of claim 34. wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, melanoma, lung cancer. pancreatic cancer, colorectal cancer, ovarian cancer, and cancers of the brain.
36. The method of claim 31. wherein the method is used to treat a cancer 5 having estramustine binding protein, or like-protein.
37. The method of claim 36, wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, and cancers of the brain.
38. The method of claim 32, wherein the method is used to treat a cancer 10 having estramustine binding protein, or like-protein.
39. The method of claim 38. wherein said cancer is selected from the group consisting of prostate cancer. breast cancer, lung cancer. pancreatic cancer. colorectal cancer, ovarian cancer, and cancers of the brain.
40. The method of claim 33, wherein the method is used to treat a cancer 15 having estramustine binding protein, or like-protein.
41. The method claim 40. wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, lung cancer. pancreatic cancer. colorectal cancer. ovarian cancer. melanoma, and cancers of the brain. 27 WO 99/49869 PCT/US99/04275
42. A method of treatment for breast cancer in which estramustine phosphate is administered intravenously.
43. A method of treatment for lung cancer in which estramustine phosphate is administered intravenously. 5
44. A method of treatment for pancreatic cancer in which estramustine phosphate is administered intravenously.
45. A method of treatment for colorectal cancer in which estramustine phosphate is administered intravenously.
46. A method of treatment for ovarian cancer in which estramustine phosphate 10 is administered intravenously.
47. A method of treatment for brain cancer in which estramustine phosphate is administered intravenously.
48. The method of claim 1, wherein the infusion is given over 30 minutes to 3 hours. 15
49. The method of claim 2. wherein the infusion is given over 30 minutes to 3 hours. 28 WO 99/49869 PCT/US99/04275
50. The method of claim 1. wherein relief from cancer-induced urinary obstruction is achieved.
51. The method of claim 2. wherein relief from cancer-induced urinary obstruction is achieved. 5
52. The method of claim 1. wherein rapid relief of cancer-induced pain is achieved.
53. The method of claim 2. wherein rapid relief of cancer-induced pain is achieved.
54. The method of claim 42, in which estramustine phosphate is administered 10 in combination with one or more other chemotherapeutic agents.
55. The method of claim 43. in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents.
56. Thile method of claim 44. in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents. 15
57. The method of claim 45, in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents. 29 WO 99/49869 PCT/US99/04275
58. The method of claim 46. in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents.
59. The method of claim 47. in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents.
60. A method of treatment for melanoma in which estramustine phosphate is administered intravenously.
61. The method of claim 60. in which estramustine phosphate is administered in combination with one or more other chemotherapeutic agents.
62. The method of claim 11. wherein said anti-microtubule agent is a taxane. I 0
63. The method of claim I 1. wherein said anti-microtubule agent is a liposome encapsulated taxane.
64. The method of claim 63. wherein said liposome encapsulated taxane is liposome encapsulated paclitaxel.
65. The method of claim 9. wherein another drug in said regimen is CPT- 11. I 5
66. The method of claim 9. wherein another drug in said regimen is doxorubicin. 30 WO 99/49869 PCT/US99/04275
67. The method of claim 9, wherein another drug in said regimen is etoposide.
68. The method of claim 9. wherein another drug in said regimen is navelbine.
69. The method of claim 9, wherein another drug in said regimen is vinblastine. 5
70. A method of potentiating the therapeutic benefit of a multi-drug chemotherapeutic regimen wherein one drug in the regimen comprises a taxane, and wherein another drug in the regimen comprises estramustine phosphate, and wherein estramustine phosphate is administered intravenously at a dosage exceeding 950 mg/m 2 . 10
71. The method of claim 15, wherein said anti-microtubule agent is a taxane.
72. The method of claim 20, wherein said anti-microtubule agent is a taxane.
73. A method of administering estramustine phosphate, wherein estramustine phosphate is first encapsulated within liposomes, and then administered intravenously.
74. A formulation of estramustine phosphate. wherein estramustine is 15 encapsulated within liposomes.
75. A method of treating cancer wherein liposome-encapsulated estramustine 31 WO 99/49869 PCT/US99/04275 phosphate is administered.
76. A chemotherapeutic agent consisting of estramustine phosphate encapsulated within liposome.
77. A method of treatment for prostate cancer, wherein liposome-encapsulated estramustine phosphate is administered.
78. A method of treatment for breast cancer, wherein liposome-encapsulated estramustine phosphate is administered.
79. A method of treatment for lung cancer, wherein liposome-encapsulated estramustine phosphate is administered. 10
80. A method of treatment for pancreatic cancer.wherein liposome encapsulated estramustine phosphate is administered.
81. A method of treatment for colorectal cancer, wherein liposome encapsulated estramustine phosphate is administered.
82. A method of treatment for ovarian cancer, wherein liposome-encapsulated 15 estramustine phosphate is administered.
83. A method of treatment for melanoma, wherein liposome-encapsulated 32 WO 99/49869 PCT/US99/04275 estramustine phosphate is administered.
84. A formulation according to claim 74 intended for intravenous administration.
85. A product. comprising estramustine phosphate suitable for intravenous 5 administration and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
86. A product according to claim 85. wherein said one or more chemotherapeutic agents are selected from the group consisting of CPT- 11, doxorubicin. etoposide, navelbine and a taxane derivative. 10
87. A product according to claim 85. wherein said estramustine phosphate suitable for intravenous administration is used as a single dosage infusion exceeding 1300 mng.
88. A product according to claim 85. wherein said estramustine phosphate suitable for intravenous administration is used as a single dosage infusion exceeding 15 950 mg/m-.
89. A product according to anyone of claims 85 to 88 for the treatment of prostate cancer, breast cancer. melanoma, lung cancer, pancreatic cancer. colorectal cancer. ovarian cancer or cancers of the brain. I,, WO 99/49869 PCT/US99/04275
90. A method for the treatment of prostate cancer, breast cancer melanoma. lung cancer, pancreatic cancer. colorectal cancer, ovarian cancer and cancers of the brain, comprising the administration of a product according to anyone of claims from 85 to 88. 34
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7954298P | 1998-03-27 | 1998-03-27 | |
| US60/079542 | 1998-03-27 | ||
| PCT/US1999/004275 WO1999049869A1 (en) | 1998-03-27 | 1999-03-26 | Methods to potentiate intravenous estramustine phosphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3353399A true AU3353399A (en) | 1999-10-18 |
| AU750010B2 AU750010B2 (en) | 2002-07-11 |
Family
ID=22151209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU33533/99A Ceased AU750010B2 (en) | 1998-03-27 | 1999-03-26 | Methods to potentiate intravenous estramustine phosphate |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1003521A4 (en) |
| JP (1) | JP2001508810A (en) |
| KR (1) | KR20010021656A (en) |
| CN (2) | CN1636598A (en) |
| AU (1) | AU750010B2 (en) |
| BR (1) | BR9906425A (en) |
| CA (1) | CA2295049A1 (en) |
| EA (1) | EA004647B1 (en) |
| HU (1) | HUP0200547A3 (en) |
| ID (1) | ID24504A (en) |
| IL (1) | IL133612A0 (en) |
| NO (1) | NO20002343D0 (en) |
| NZ (1) | NZ501987A (en) |
| PL (1) | PL342969A1 (en) |
| WO (1) | WO1999049869A1 (en) |
| ZA (1) | ZA997821B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003201D0 (en) * | 2000-02-11 | 2000-04-05 | Pharmacia & Upjohn Spa | Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| US6436913B1 (en) * | 2000-07-25 | 2002-08-20 | Pharmacia & Upjohn Company | Use of estramustine phosphate in the treatment of bone metastasis |
| RU2471511C1 (en) * | 2011-05-04 | 2013-01-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) | Method of treating colonic liver metastases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617292A (en) * | 1984-06-20 | 1986-01-13 | Japan Atom Energy Res Inst | Method for producing an estracytic compound bound to an anticancer drug |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (en) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS. |
| PT706373E (en) * | 1992-03-23 | 2000-11-30 | Univ Georgetown | TAXOL ENCAPSULATED IN A LIPOSOM AND A METHOD |
| FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
-
1999
- 1999-03-26 CN CNA2004100867183A patent/CN1636598A/en active Pending
- 1999-03-26 NZ NZ501987A patent/NZ501987A/en unknown
- 1999-03-26 BR BR9906425-1A patent/BR9906425A/en not_active IP Right Cessation
- 1999-03-26 PL PL99342969A patent/PL342969A1/en unknown
- 1999-03-26 EA EA199901081A patent/EA004647B1/en not_active IP Right Cessation
- 1999-03-26 KR KR1020007000214A patent/KR20010021656A/en not_active Ceased
- 1999-03-26 WO PCT/US1999/004275 patent/WO1999049869A1/en not_active Ceased
- 1999-03-26 CA CA002295049A patent/CA2295049A1/en not_active Abandoned
- 1999-03-26 JP JP54936999A patent/JP2001508810A/en not_active Ceased
- 1999-03-26 CN CN99800823A patent/CN1273530A/en active Pending
- 1999-03-26 IL IL13361299A patent/IL133612A0/en not_active IP Right Cessation
- 1999-03-26 HU HU0200547A patent/HUP0200547A3/en unknown
- 1999-03-26 AU AU33533/99A patent/AU750010B2/en not_active Ceased
- 1999-03-26 ID IDW20000105A patent/ID24504A/en unknown
- 1999-03-26 EP EP99914884A patent/EP1003521A4/en not_active Withdrawn
- 1999-12-22 ZA ZA9907821A patent/ZA997821B/en unknown
-
2000
- 2000-05-04 NO NO20002343A patent/NO20002343D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200547A2 (en) | 2002-07-29 |
| NZ501987A (en) | 2002-10-25 |
| NO20002343L (en) | 2000-05-04 |
| WO1999049869A1 (en) | 1999-10-07 |
| HUP0200547A3 (en) | 2003-07-28 |
| KR20010021656A (en) | 2001-03-15 |
| ZA997821B (en) | 2000-08-01 |
| IL133612A0 (en) | 2001-04-30 |
| EP1003521A1 (en) | 2000-05-31 |
| BR9906425A (en) | 2000-07-11 |
| ID24504A (en) | 2000-07-20 |
| CN1636598A (en) | 2005-07-13 |
| NO20002343D0 (en) | 2000-05-04 |
| AU750010B2 (en) | 2002-07-11 |
| CA2295049A1 (en) | 1999-10-07 |
| EA004647B1 (en) | 2004-06-24 |
| PL342969A1 (en) | 2001-07-16 |
| EP1003521A4 (en) | 2003-07-23 |
| CN1273530A (en) | 2000-11-15 |
| EA199901081A1 (en) | 2000-12-25 |
| JP2001508810A (en) | 2001-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6461637B1 (en) | Method of administering liposomal encapsulated taxane | |
| US6146659A (en) | Method of administering liposomal encapsulated taxane | |
| US7060828B2 (en) | Liposomal camptothecins and uses thereof | |
| AU744095B2 (en) | Methods and compositions for treatment of ovarian cancer | |
| AU779922B2 (en) | Formulations for parenteral use of estramustine phosphate and amino acids | |
| AU750010B2 (en) | Methods to potentiate intravenous estramustine phosphate | |
| US6849616B1 (en) | Methods to potentiate intravenous estramustine phosphate | |
| Frasci et al. | Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study | |
| de Souza et al. | 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. | |
| MXPA00000198A (en) | Methods to potentiate intravenous estramustine phosphate | |
| Hooper et al. | Identification and development of vascular disrupting agents: natural products that interfere with tumor growth | |
| CZ465599A3 (en) | Potentiation methods of intravenous estramustinphosphate | |
| US7314637B1 (en) | Method of administering liposomal encapsulated taxane | |
| Diaz-Rubio et al. | The Antiemetic Efficacy of Thiethylperazine and Methylprednisolone Versus Thiethylperazine and Placebo in Breast Cancer Patients Treated with Adjuvant Chemotherapy (Fluorouracil, Doxorubicin and Cyclophosphamide): A randomized, double-blind, cross-over trial | |
| WO2001070220A1 (en) | A method of administering liposomal encapsulated taxane | |
| ZA200508696B (en) | Use of irinotecan for treatment of resistant breast cancer | |
| Martin | Strategies for new drugs and their | |
| Robertson | Antivascular Agents | |
| MXPA00002170A (en) | A method of administering liposomal encapsulated taxane | |
| ZA200100454B (en) | A method of administering liposomal encapsulated taxane. | |
| CZ339299A3 (en) | Use of taxane for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |